Cholesteatoma- an Immune disease
Clicks: 1
ID: 314959
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #25 of 30 articles by views in Clinical & Experimental Immunology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Cholesteatoma is abnormal epithelial tissue in the middle ear cleft and an important cause of chronically discharging ears and hearing loss. Its proximity to important middle ear structures and the brain can lead to significant complications. Cholesteatoma presents both as congenital and acquired types and can occur both in children and adults. The mainstay of treating cholesteatoma is a destructive surgery with attendant morbidity. Despite radical surgery cholesteatomas can recur, sometimes repeatedly, causing a significant impact on quality of life. The role of inflammation in cholesteatoma is an area of keen interest. However, immune processes are highly complex, and while various individual components of the process have been studied in cholesteatoma, we are far from a cohesive understanding of the role of immune cells and inflammation pathways in the pathogenesis of cholesteatoma. Better understanding of its immune-pathogenesis would enable identification of disease-modifying therapies and novel pharmacological targets. In this review, we provide a detailed overview of the existent knowledge and recent developments on immune cells and inflammatory pathways implicated in cholesteatoma pathogenesis, progression and damaging bone eroding properties. As cholesteatoma surgery is inherently destructive with poor hearing results there is a definite necessity for new treatments to reduce the surgical burden and enable functional preservation in the management of this condition. We focus on the current and future areas of research that could lead to new therapies targeting inflammation and bring about a step change in the management of this aggressive ear condition.
| Reference Key |
openalex_W7162466827
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Aagat Khatiwada, Mohammed Elkrim Mohammed, Ingrid E. Dumitriu, Paramita Baruah |
| Journal | Clinical & Experimental Immunology |
| Year | 2026 |
| DOI |
10.1093/cei/uxag030
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.